Login
From:
Forbes
(Uncensored)
subscribe
Why These Investment Firms Bet $400 Million On A Chinese Ozempic Rival
https://www.forbes.com/sites/amyfeldman/2025/04/12/this-pharma-company-is-betting-big-on-a-chinese-ozempic-rival/
links
backlinks
Tagged with:
healthcare
Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is quickly emerging as a powerhouse pharmaceutical R&D center.
Roast topics
Find topics
Find it!
